↓ Skip to main content

Dove Medical Press

Article Metrics

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab

Overview of attention for article published in Vascular Health and Risk Management, January 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (73rd percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

policy
1 policy source
twitter
4 tweeters

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
30 Mendeley
Title
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
Published in
Vascular Health and Risk Management, January 2016
DOI 10.2147/vhrm.s102564
Pubmed ID
Authors

Dirk Blom, Ricardo Dent, Rita Castro, Peter Toth, Blom, Dirk J, Dent, Ricardo, Castro, Rita C, Toth, Peter P, Dirk J Blom, Rita C Castro, Peter P Toth

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases low-density lipoprotein cholesterol (LDL-C) concentrations through interference with normal physiologic hepatic LDL receptor (LDLR) recycling. Inhibiting PCSK9 results in improved LDLR recycling, increased LDLR availability on hepatocyte cell surfaces, and reduced blood LDL-C levels, making PCSK9 inhibition a novel therapeutic strategy for managing hypercholesterolemia. Monoclonal antibodies directed against PCSK9 have been developed for this purpose. A large number of clinical trials have demonstrated that monoclonal antibodies against PCSK9 yield substantial reductions in LDL-C when administered as monotherapy or in combination with statins to patients with nonfamilial and familial forms of hypercholesterolemia. Data from long-term trials demonstrate that the LDL-C-lowering effect of PCSK9 inhibitors is durable. These agents are generally well tolerated, and few patients discontinue treatment due to adverse events. Moreover, PCSK9 inhibitors do not appear to elicit the hepatic and muscle-related side effects associated with statin use. The ultimate value of PCSK9 inhibitors will be measured by their effect on clinical outcomes. Early evidence of a reduction in cardiovascular events after 1 year of treatment was shown in a prospective exploratory analysis of two ongoing long-term open-label extension evolocumab trials. Similarly, cardiovascular events were reduced in another exploratory analysis after >1 year of therapy with alirocumab. For the primary care physician, PCSK9 inhibitors represent a welcome additional option for lowering LDL-C in patients with familial forms of hypercholesterolemia and those with clinical atherosclerotic cardiovascular disease who are on maximally tolerated statin therapy.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 3%
Unknown 29 97%

Demographic breakdown

Readers by professional status Count As %
Unspecified 6 20%
Student > Bachelor 5 17%
Student > Master 4 13%
Student > Postgraduate 4 13%
Student > Ph. D. Student 4 13%
Other 7 23%
Readers by discipline Count As %
Medicine and Dentistry 9 30%
Unspecified 8 27%
Pharmacology, Toxicology and Pharmaceutical Science 4 13%
Agricultural and Biological Sciences 3 10%
Neuroscience 3 10%
Other 3 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 June 2016.
All research outputs
#2,802,925
of 12,197,635 outputs
Outputs from Vascular Health and Risk Management
#102
of 524 outputs
Outputs of similar age
#71,563
of 276,298 outputs
Outputs of similar age from Vascular Health and Risk Management
#3
of 15 outputs
Altmetric has tracked 12,197,635 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 524 research outputs from this source. They receive a mean Attention Score of 3.7. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,298 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.